EICHORCondition: Advanced Solid Tumor · Solid Tumor · Sponsor: BeOne Medicines
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
This description comes directly from the study's public registry record.
Study Director · 1.877.828.5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| University of Southern California Norris Comprehensive | Los Angeles, California, United States | Recruiting |
| Yale University Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Sylvester Cancer Center, University of Miami | Miami, Florida, United States | Recruiting |
| University of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| John Theurer Cancer Center Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Icahn School of Medicine At Mount Sinai | New York, New York, United States | Recruiting |
| Providence Portland Medical Center | Portland, Oregon, United States | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Southside Cancer Care | Miranda, New South Wales, Australia | Completed |
| Macquarie University | North Ryde, New South Wales, Australia | Recruiting |
| Icon Cancer Centre Kurralta Park | Kurralta Park, South Australia, Australia | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05981703